<DOC>
	<DOCNO>NCT00987584</DOCNO>
	<brief_summary>This study Molecular Cellular Characterization Myelodysplastic Syndromes ( MDS ) ( eProtocol 15369 ) . The purpose propose study analyze exist sample take participant participate clinical trial evaluate efficacy safety investigational agent ON 01910.Na ( eProtocol 16214 ) . This study use exist blood marrow sample determine rate duration objective hematologic marrow response , duration progression-free survival ON01910.Na-treated MDS patient . This study use exist blood marrow sample determine rate duration objective hematologic marrow response , duration progression-free survival ON01910.Na-treated MDS patient .</brief_summary>
	<brief_title>Phase II Cont . IV ON 01910.Na MDS w/ Trisomy 8/Intermed-1 , 2/High Risk</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Trisomy</mesh_term>
	<criteria>Diagnosis IPSS Intermediate High risk MDS bone marrow biopsy , marrow cytogenetics blood count , use FAB morphologic criterion Eastern Cooperative Oncology ( ECOG ) performance status 02 Adequate Liver Function , evidence serum bilirubin less equal 1.5 time laboratory normal range ( except patient confirm diagnosis Gilberts Disease ) ALT AST 3 time laboratory normal range A serum creatinine concentration less equal 2mg/dl Subjects must equal great 18 year age time obtain informed consent Written inform consent Prior history leukemia aplastic anemia Prior history bone marrow transplantation Platelet count &lt; 100,000/mm^3 *Prior malignancy ( situ cervical cancer , control prostate cancer , basal cell cancer skin ) unless treat curative intent without evidence disease great equal 3 year randomization Active uncontrolled infection Unstable angina , congestive heart failure [ NYHA &gt; classII ] , uncontrolled hypertension [ diastolic &gt; 100mmHg ] , uncontrolled cardiac arrhythmia , recent ( within 1 year ) myocardial infarction Less 4 week since receipt investigational product device Pregnant breast feeding Subjects reproductive potential use adequate contraceptive precaution , judgment investigator Previously enrol study Will available followup assessment Any disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>